glp-1 diarrhea Adverse effects of class drugs. Gastrointestinal issues are Q&A: Liraglutide outperforms colesevelam in
Description
Gentle styling and reduced heat
2025;45:e70407
Your cart is currently empty
Novo Nordisk, the Danish pharma company behind several GLP-1RA drugs (including Ozempic/Wegovy and Saxenda) grew its sales by over 30% in 2023, and its share price rose by over 70% in the last year, making it the most valuable European company by market capitalization
[DOI] [PubMed] [Google Scholar] 35.Kadouh H, Chedid V, Halawi H, et al
